Dynavax Issues Update on HEPLISAV's Regulatory Path, Will Host Call Tomorrow
October 16, 2013 at 17:10 PM EDT
Dynavax Technologies Corporation (NASDAQ: DVAX ) today announced the design of its next large-scale clinical study of HEPLISAV, its investigational adult hepatitis B vaccine, following discussions with the U.S. Food and Drug Administration (FDA or Agency). The planned study, HBV-23, is intended to provide a sufficiently-sized safety database for the Agency to complete its review
